Introduction and Acknowledgements
Welcome to BioPharm International's Guide to Formulation, Fill, and Finish, focused on pharmaceuticals — mainly proteins — produced by biologic means.
Welcome to BioPharm International's Guide to Formulation, Fill, and Finish, focused on pharmaceuticals — mainly proteins — produced by biologic means. Because of the tremendous development costs and the special needs of fragile proteins (most of which must be delivered by injection), the early and continuing efforts of those who determine the "recipe" and assure its stability and effectiveness are critical to the complex, interconnected stages of drug development.
The development process does not even begin until formulators accumulate enough data to assure that the drug candidate has a chance of succeeding. Bioanalysts ensure that the protein of interest remains viable through all stages of development and scale-up. Formulators examine how the product should be packaged, what it will be mixed with, how long it will last on the shelf (and under what conditions). Even before they know whether the drug will be tolerated by human subjects in clinical trials, they must decide whether it will be a liquid or freeze-dried formulation. They even have to consider, years before the drug may be approved, whether the ingredients they use are allowed in other countries in which the drug might be marketed.
The means of delivery into the patient's body isn't the only type of "drug delivery" of concern here. A biopharmaceutical has to get from the manufacturer to the clinic in the first place without suffering damage from heat, cold, or other physical stresses that occur during transportation. And with that need, a whole new set of regulations comes into play.
Acknowledgements
BioPharm International
thanks the following industry professionals for their help in preparing this guide.
Siddarth Advant, Director of Pharmaceutical Sciences and Stability, Diosynth
Tom Anchordoquy, Assistant Professor, University of Colorado School of Pharmacy
William M. Arden, Marketing Manager, Bosch Packaging Technology
Narlin Beaty, Chief Technical Officer, Chesapeake Biological Laboratories
Frank Bedu-Addo, Vice President, Purification Operations and Biopharmaceutics, KBI BioPharma
John Bontempo, Consultant in Biopharmaceutical Product Development
John Carpenter, Associate Professor, University of Colorado School of Pharmacy
Rajesh K. Gupta, Senior Consultant, Biologics Consulting Group
Chris Holloway, Group Director of Regulatory Affairs, ERA Consulting Group
Jean Huxsoll, Senior Director, QA, Chiron
Rajesh Krishnamurthy, Scientist in Formulation and Stability, Human Genome Sciences
John McEntire, Pharmaceutical Development Consultant
Tom Ransohoff, Senior Consultant, BioProcess Technology Consultants
Una S. Ryan, Chief Executive Officer, AVANT Immunotherapeutics
Bret Shirley, Senior Scientist in Formulation Development, Chiron
Krish Venkat, Director, Analytical Services, GlaxoSmithKline
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
